Loading…
Academic Journal
Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts
Rodrigo Athanazio, Mônica Corso Pereira, Georgina Gramblicka, Fernando Cavalcanti-Lundgren, Mara Fernandes de Figueiredo, Francisco Arancibia, Samia Rached, David de la Rosa, Luis Máiz-Carro, Rosa Girón, Casilda Olveira, Concepción Prados, Miguel Angel Martinez-Garcia
BMC Pulmonary Medicine, Vol 17, Iss 1, Pp 1-9 (2017)
Saved in:
| Title | Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts |
|---|---|
| Authors | Rodrigo Athanazio, Mônica Corso Pereira, Georgina Gramblicka, Fernando Cavalcanti-Lundgren, Mara Fernandes de Figueiredo, Francisco Arancibia, Samia Rached, David de la Rosa, Luis Máiz-Carro, Rosa Girón, Casilda Olveira, Concepción Prados, Miguel Angel Martinez-Garcia |
| Publication Year |
2017
|
| Source |
BMC Pulmonary Medicine, Vol 17, Iss 1, Pp 1-9 (2017)
|
| Description |
Abstract Background The FACED score is an easy-to-use multidimensional grading system that has demonstrated an excellent prognostic value for mortality in patients with bronchiectasis. A Spanish group developed the score but no multicenter international validation has yet been published. Methods Retrospective and multicenter study conducted in six historical cohorts of patients from Latin America including 651 patients with bronchiectasis. Clinical, microbiological, functional, and radiological variables were collected, following the same criteria used in the original FACED score study. The vital status of all patients was determined in the fifth year of follow-up. The area under ROC curve (AUC-ROC) was used to calculate the predictive power of the FACED score for all-cause and respiratory deaths and both number and severity of exacerbations. The discriminatory power to divide patients into three groups of increasing severity was also analyzed. Results Mean (SD) age of 48.2 (16), 32.9% of males. The mean FACED score was 2.35 (1.68). During the follow up, 95 patients (14.6%) died (66% from respiratory causes). The AUC ROC to predict all-cause and respiratory mortality were 0.81 (95% CI: 0.77 to 0.85) 0.84 (95% CI: 0.80 to 0.88) respectively, and 0.82 (95% CI: 078–0.87) for at least one hospitalization per year. The division into three score groups separated bronchiectasis into distinct mortality groups (mild: 3.7%; moderate: 20.7% and severe: 48.5% mortality; p
|
| Document Type |
article
|
| Language |
English
|
| Publisher Information |
BMC, 2017.
|
| Subject Terms | |
